Drug Trial Radar · NCT00265811
Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery
Last checked: Nov 20, 2026Latest source record: Nov 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,559
Actual
Start
Nov 2005
Primary completion
Nov 2009
Study completion Jun 22, 2010
Sponsor
- Lead sponsor
- Federation Francophone de Cancerologie DigestiveAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, or fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy with or without cetuximab after surgery may kill any remaining tumor cells and keep colon cancer from coming back. It is not yet known whether giving combination chemotherapy together with cetuximab is more effective than giving combination chemotherapy alone in treating colon cancer. PURPOSE: This randomized phase III trial is studying combination chemotherapy and cetuximab to see how well they work compared to combination chemotherapy alone in treating patients with stage III colon cancer that was completely removed by surgery.
Conditions
- Colorectal Cancer
Interventions
FolfoxDrug
CetuximabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survivalTime frame: 3-years DFS
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Hopital Duffaut
Avignon, France
CHU de Caen
Caen, France
Hopital Robert Boulin
Libourne, France
Hopital Bichat - Claude Bernard
Paris, France
CHU Pitie-Salpetriere
Paris, France
Hopital Tenon
Paris, France
Centre Hospitalier Yves Le Foll
Saint-Brieuc, France
Nouvelle Clinique Generale
Valence, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.